Overview

Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the overall survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.
Phase:
Phase 2
Details
Lead Sponsor:
Peregrine Pharmaceuticals
Treatments:
Antibodies, Monoclonal
Bavituximab
Gemcitabine